Evasion of cell death is a hallmark of cancer cells that enables them to overcome endogenous barriers to cancer development and to resist treatment. Insights into the many facets of cell death, ...

Accurately counting viable cells in a sample is crucial for various biological assays, including normalization and assessing drug impacts on cell proliferation for cancer research. Regular cell ...

Cell viability constitutes a fundamental measure in biomedical research, serving as an essential indicator of cellular health, metabolic activity and the efficacy of pharmacological treatments. Among ...

Amerigo Scientific’s cell proliferation assays are developed to provide scientists with an easily accessible source of first-hand information concerning disease pathways, therapeutic activity, and ...

Researchers explored why only 40 percent of patients responded to Amgen's Imdelltra using TellBio's liquid biopsy test and ...

Cell-Based Assays are expanding post-pandemic, driven by new tech enabling comprehensive cell function measurements. They're pivotal in biotech, with growth fueled by advancements in genomics and ...

Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials A total of 871 patient ...

Adherent cell assays have lagged behind in automation, slowing drug discovery. Semarion’s SemaCyte® microcarrier platform streamlines these workflows by making adherent cells assay-ready, improving ...

Most cells in the human body exist in complex three-dimensional environments, yet they are still commonly studied on flat plastic dishes. These two-dimensional cultures distort cell behavior, limiting ...

BACKGROUND: The disruption of the blood–brain barrier (BBB) is a central pathogenic event in many central nervous system disorders. However, the mechanisms regulating BBB function remain incompletely ...

Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...